| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,099 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Petit Robert |
Chief Scientific Officer |
• – – |
2014-11-28 |
4 |
D |
$3.12 |
$253 |
D/D |
(81) |
111,871 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2014-11-28 |
4 |
A |
$3.12 |
$1,863 |
D/D |
597 |
111,952 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• • – |
2014-11-28 |
4 |
A |
$3.12 |
$6,249 |
D/D |
2,003 |
303,139 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2014-11-28 |
4 |
D |
$3.12 |
$187 |
D/D |
(60) |
118,029 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2014-11-28 |
4 |
A |
$3.12 |
$1,529 |
D/D |
490 |
118,089 |
|
- |
|
| Appel Roni |
Director |
– • – |
2014-11-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(33,636) |
83,695 |
|
- |
|
| Berman Richard J |
Director |
– • – |
2014-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
33,762 |
83,762 |
|
- |
|
| Sidransky David |
Director |
– • – |
2014-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
25,115 |
85,419 |
|
- |
|
| Khleif Samir N |
Director |
– • – |
2014-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
25,115 |
51,157 |
|
- |
|
| Patton James P |
Director |
– • – |
2014-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
33,762 |
192,290 |
|
- |
|
| Appel Roni |
Director |
– • – |
2014-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
25,115 |
108,810 |
|
- |
|
| Mckearn Thomas J |
Director |
– • – |
2014-11-03 |
4 |
D |
$3.04 |
$40,809 |
D/D |
(13,424) |
85,220 |
|
- |
|
| Mckearn Thomas J |
Director |
– • – |
2014-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
25,115 |
98,644 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2014-10-31 |
4 |
D |
$3.18 |
$10,926 |
D/D |
(2,758) |
111,355 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2014-10-31 |
4 |
A |
$3.18 |
$1,876 |
D/D |
590 |
111,577 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• • – |
2014-10-31 |
4 |
A |
$3.18 |
$6,255 |
D/D |
1,967 |
301,136 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2014-10-31 |
4 |
D |
$3.18 |
$80 |
D/D |
(25) |
135,335 |
|
- |
|
| Mauro David J |
Chief Medical Officer |
• – – |
2014-10-31 |
4 |
A |
$3.18 |
$604 |
D/D |
190 |
135,360 |
|
- |
|
| French Christy Lee |
VP-Regulatory, Medical Affairs |
• – – |
2014-10-31 |
4 |
D |
$3.18 |
$8,351 |
D/D |
(2,094) |
71,597 |
|
- |
|
| French Christy Lee |
VP-Regulatory, Medical Affairs |
• – – |
2014-10-31 |
4 |
A |
$3.18 |
$827 |
D/D |
260 |
71,700 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2014-10-31 |
4 |
D |
$3.18 |
$216 |
D/D |
(68) |
85,536 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2014-10-31 |
4 |
A |
$3.18 |
$1,297 |
D/D |
408 |
85,604 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2014-10-31 |
4 |
D |
$3.18 |
$184 |
D/D |
(58) |
117,599 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2014-10-31 |
4 |
A |
$3.18 |
$1,530 |
D/D |
481 |
117,657 |
|
- |
|
| Khleif Samir N |
Director |
– • – |
2014-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
26,042 |
26,042 |
|
- |
|
465 Records found
|
|
Page 16 of 19 |
|
|
